Grippferon, drops 10000 me/ml 10 ml

Pharmgroup:

IBP – cytokine.

Pharmacological action:

The drug has immunomodulatory, anti-inflammatory and antiviral action.

Pharmacokinetics:

When administered intranasally, the concentration of the active substance reached in the blood is well below the detection limit (the detection limit for interferon alfa-2b is 1-2 IU/mL) and is of no clinical significance.

Indications

Prevention and treatment of influenza and ARVI in children from birth and adults, including pregnant women.

Pharmacological effect

Pharmaceutical group:

MIBP is a cytokine.

Pharmaceutical action:

The drug has immunomodulatory, anti-inflammatory and antiviral effects.

Pharmacokinetics:

When administered intranasally, the concentration of the active substance achieved in the blood is significantly lower than the detection limit (detection limit of interferon alpha-2b – 1-2 IU/ml) and has no clinical significance.

Special instructions

The simultaneous use of intranasal vasoconstrictor drugs is not recommended due to the increased drying effect on the nasal mucosa.

Active ingredient

Interferon alpha-2b

Composition

1 ml of solution contains recombinant alpha-2 human interferon of at least 10,000 IU.

Pregnancy

Approved for use during the entire period of pregnancy.

Contraindications

– Individual intolerance to interferon drugs and components included in the drug Grippferon.
– Severe forms of allergic diseases.

Side Effects

Allergic reactions.

Storage conditions

At 2–8 °C

Shelf life

2 years

Manufacturer

Firn M, Russia